UNITED THERAPEUTICS Corp
For the period ended Jun 30, 2024. Filed Jul 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Jul 31, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)Trading Plans
On May 17, 2024, James Edgemond, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 100,000 stock options, and to sell up to 80,000 shares of common stock received upon exercise of such stock options, subject to certain conditions.
On June 20, 2024, Paul Mahon, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 91,250 STAP awards, subject to certain conditions.
During the three months ended June 30, 2024, no director or Section 16 officer terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).
| 56 | United Therapeutics, a public benefit corporation |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.